Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder
Manoj K. Doss, Michal Považan, Monica D. Rosenberg, et al.
Translational Psychiatry (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 236

Showing 1-25 of 236 citing articles:

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder
Michael P. Bogenschutz, Stephen Ross, Snehal Bhatt, et al.
JAMA Psychiatry (2022) Vol. 79, Iss. 10, pp. 953-953
Open Access | Times Cited: 422
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
Natalie Gukasyan, Alan K. Davis, Frederick S. Barrett, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 2, pp. 151-158
Open Access | Times Cited: 300
Towards an understanding of psychedelic-induced neuroplasticity
Abigail E. Calder, Gregor Hasler
Neuropsychopharmacology (2022) Vol. 48, Iss. 1, pp. 104-112
Open Access | Times Cited: 183
The neural basis of psychedelic action
Alex C. Kwan, David E. Olson, Katrin H. Preller, et al.
Nature Neuroscience (2022) Vol. 25, Iss. 11, pp. 1407-1419
Closed Access | Times Cited: 167
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
Michiel van Elk, David B. Yaden
Neuroscience & Biobehavioral Reviews (2022) Vol. 140, pp. 104793-104793
Open Access | Times Cited: 113
Default Mode Network Modulation by Psychedelics: A Systematic Review
James J Gattuso, Daniel Perkins, Simon Ruffell, et al.
The International Journal of Neuropsychopharmacology (2022) Vol. 26, Iss. 3, pp. 155-188
Open Access | Times Cited: 109
Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study
Stephanie Knatz Peck, Samantha Shao, Tessa Gruen, et al.
Nature Medicine (2023) Vol. 29, Iss. 8, pp. 1947-1953
Open Access | Times Cited: 70
Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey
Sandeep M. Nayak, Hillary Jackson, Nathan D. Sepeda, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 44
Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis
Yuan Yao, Dan Guo, Tangsheng Lu, et al.
Psychiatry Research (2024) Vol. 335, pp. 115886-115886
Closed Access | Times Cited: 27
Expectancy Effects in Psychedelic Trials
Balázs Szigeti, Boris D. Heifets
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2024) Vol. 9, Iss. 5, pp. 512-521
Closed Access | Times Cited: 24
Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
Athina-Marina Metaxa, Mike Clarke
BMJ (2024), pp. e078084-e078084
Open Access | Times Cited: 24
Treatment-Resistant Depression in Older Adults
David C. Steffens
New England Journal of Medicine (2024) Vol. 390, Iss. 7, pp. 630-639
Open Access | Times Cited: 21
Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial
Broc A. Pagni, Richard J. Zeifman, Sarah E. Mennenga, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 114-125
Closed Access | Times Cited: 2
Canalization and plasticity in psychopathology
Robin Carhart‐Harris, Shamil Chandaria, David Erritzøe, et al.
Neuropharmacology (2022) Vol. 226, pp. 109398-109398
Open Access | Times Cited: 66
Understanding the effects of serotonin in the brain through its role in the gastrointestinal tract
James M. Shine, Claire O’Callaghan, Ishan C. Walpola, et al.
Brain (2022) Vol. 145, Iss. 9, pp. 2967-2981
Closed Access | Times Cited: 44
Acute psilocybin enhances cognitive flexibility in rats
Alejandro Torrado Pacheco, Randall J. Olson, Gabriela Garza, et al.
Neuropsychopharmacology (2023) Vol. 48, Iss. 7, pp. 1011-1020
Open Access | Times Cited: 41
Mini-review: The neurobiology of treating substance use disorders with classical psychedelics
Marvin M. Urban, Moritz R. Stingl, Marcus W. Meinhardt
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 40
Sustained effects of single doses of classical psychedelics in humans
Gitte M. Knudsen
Neuropsychopharmacology (2022) Vol. 48, Iss. 1, pp. 145-150
Open Access | Times Cited: 39
Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study
Natasha L. Mason, Attila Szabó, Kim P. C. Kuypers, et al.
Brain Behavior and Immunity (2023) Vol. 114, pp. 299-310
Open Access | Times Cited: 39
Psychedelic therapy in the treatment of addiction: the past, present and future
Rayyan Zafar, Maxim Siegel, Rebecca Harding, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 38
How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change
Richard J. Zeifman, Anne Catherine Wagner, Candice M. Monson, et al.
Journal of Affective Disorders (2023) Vol. 334, pp. 100-112
Open Access | Times Cited: 31
Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?
M. Ishrat Husain, Nicole Ledwos, Elise Fellows, et al.
Frontiers in Psychiatry (2023) Vol. 13
Open Access | Times Cited: 30
Therapeutic mechanisms of psychedelics and entactogens
Boris D. Heifets, David E. Olson
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 104-118
Closed Access | Times Cited: 29
The costs and benefits of psychedelics on cognition and mood
Ceyda Sayalı, Frederick S. Barrett
Neuron (2023) Vol. 111, Iss. 5, pp. 614-630
Open Access | Times Cited: 26
Clinical specificity profile for novel rapid acting antidepressant drugs
Mauro Scala, Giuseppe Fanelli, Diana De Ronchi, et al.
International Clinical Psychopharmacology (2023) Vol. 38, Iss. 5, pp. 297-328
Open Access | Times Cited: 26
Page 1 - Next Page

Scroll to top